ABL Bio

ABL Bio ROA

The Return on Assets (ROA) of ABL Bio (298380.KQ) as of Nov 22, 2026 is -13.46 %. In the previous year, Return on Assets (ROA) was -23.94 % — a change of -43.78% (higher).

ROA

-13.46 %

YoY

-43.78%

Last updated:

In 2025, ABL Bio's return on assets (ROA) was -13.46 %, a -43.78% increase from the -23.94 % ROA in the previous year.

The ABL Bio ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2018
-69.42 KRW
Jan 1, 2019
-25.89 KRW
Jan 1, 2020
-55.66 KRW
Jan 1, 2021
-66.55 KRW
Jan 1, 2022
1.73 KRW
Jan 1, 2023
-1.65 KRW
Jan 1, 2024
-23.94 KRW
Jan 1, 2025
-13.46 KRW
The ABL Bio ROA history
YEARROAYoY
-13.46 %-43.78%
-23.94 %+1,348.42%
-1.65 %-195.38%
1.73 %-102.60%
-66.55 %+19.55%
-55.66 %+114.96%
-25.89 %-62.70%
-69.42 %-81.08%
-366.89 %+101.89%
-181.73 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ABL Bio Stock analysis

What does ABL Bio do? ABL Bio, Inc. develops therapeutic drugs for immuno-oncology and neurodegenerative diseases, focusing on anti-angiogenesis antibodies, anti-tumor targeting antibodies, T cell engager bispecific antibodies (TCEs), dual immune cell targeting bispecific antibodies (DICs), novel immune cell targeting antibodies (NICs), brain disease dual antibodies, and antibody-drug conjugates (ADCs). The company generates revenue through the development and commercialization of these advanced biopharmaceutical products, targeting pharmaceutical companies and research institutions seeking innovative treatments for cancer and neurological disorders. Its product portfolio addresses unmet medical needs in oncology and neurology, with a focus on next-generation antibody-based therapies. The company's pipeline includes multiple proprietary drug candidates designed to enhance treatment efficacy and patient outcomes in complex disease areas. ABL Bio, Inc. serves pharmaceutical companies and research institutions as its primary customers, providing them with proprietary antibody technologies and drug candidates for further development and potential commercialization. The company's products are positioned within the immuno-oncology and neurodegenerative disease segments, where demand for targeted therapies is growing. By developing novel antibody-based treatments, ABL Bio aims to capture market share in high-growth therapeutic areas, leveraging its expertise in bispecific and dual-targeting antibody platforms to address complex medical challenges. ABL Bio is one of the most popular companies on Eulerpool.

ROA Details

Understanding ABL Bio's Return on Assets (ROA)

ABL Bio's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing ABL Bio's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider ABL Bio's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in ABL Bio’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about ABL Bio stock

Return on Assets (ROA) of ABL Bio is -13.46 % in 2025.

Return on Assets (ROA) of ABL Bio changed from -23.94 % to -13.46 %, representing a -43.78% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) ABL Bio since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s ABL Bio with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — ABL Bio

All Key Metrics — ABL Bio